Germany's Nitrendipine Shortage Forces Patients to Seek Blood Pressure Alternatives

Patients in Germany relying on nitrendipine, a widely used calcium channel blocker, are facing ongoing supply issues. The shortages, affecting both 10 mg and 20 mg doses, have persisted since last summer and now involve four major manufacturers. Regulators have flagged the problem as part of broader drug scarcity affecting older medications across the country.

The drug shortages stem from production problems reported by four key producers: Aristo, Ratiopharm, Aliud Pharma, and AbZ. All have confirmed interruptions in supplying both strengths of nitrendipine. Aristo's 20 mg formulation will remain unavailable until at least the end of 2023, while Ratiopharm and Aliud expect to resume deliveries by late March. AbZ anticipates a later return, with restocking planned for the end of May.

Calcium channel blockers like nitrendipine work by preventing calcium from entering cells, which helps keep arteries relaxed and lowers blood pressure. These drugs fall into three main groups: nifedipine-type, verapamil-type, and diltiazem-type. Timing for doses varies—some must be taken with meals, others afterward—while common side effects include low blood pressure, headaches, flushing, and irregular heartbeats. With nitrendipine in short supply, doctors are increasingly turning to alternatives. Amlodipine and lercanidipine, two other calcium channel blockers, have become the most prescribed substitutes in clinical practice. The shortages highlight wider challenges in maintaining steady supplies of older but essential medications.

The ongoing nitrendipine shortage means patients may need to switch to alternative treatments for the foreseeable future. While some manufacturers plan to resume production within months, Aristo's 20 mg shortage will last until the end of the year. Regulators continue to monitor the situation as part of broader efforts to address drug supply gaps in Germany.